Related Experiment Video
Updated: May 23, 2026

Characterization of Complex Systems Using the Design of Experiments Approach: Transient Protein Expression in Tobacco as a Case Study
Published on: January 31, 2014
Fitting E(max) models to clinical trial dose-response data
Simon Kirby1, Phil Brain, Byron Jones
1Simon Kirby, Statistics, Pfizer Limited, Sandwich, Kent, UK. simon.kirby@pfizer.com
Abstract:
We consider fitting Emax models to the primary endpoint for a parallel group dose–response clinical trial. Such models can be difficult to fit using Maximum Likelihood if the data give little information about the maximum possible response. Consequently, we consider alternative models that can be derived as limiting cases, which can usually be fitted. Furthermore we propose two model selection procedures for choosing between the different models. These model selection procedures are compared with two model selection procedures which have previously been used. In a simulation study we find that the model selection procedure that performs best depends on the underlying true situation. One of the new model selection procedures gives what may be regarded as the most robust of the procedures.
Related Concept Videos
Pharmacodynamic Models: Emax Drug–Concentration Effect Model
Pharmacodynamic Models: Linear Concentration–Effect Model
Pharmacodynamic Models: Additive and Proportional Drug Effect Model
Pharmacodynamic Models: Direct Effect Model and Indirect Response Model
Pharmacodynamic Models: Overview
Pharmacodynamic Models: Logarithmic Concentration–Effect Model
